Melatonin in the pathogenesis of preeclampsia
Journal of obstetrics and women's diseases · 2022
DOI: 10.17816/jowd103863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of obstetrics and women's diseases, 2022. Verfasst von Inna I. Evsyukova und 1 weiteren Autor:innen. Die Arbeit nennt 79 Literaturangaben.
Abstract (Originalsprache)
The review presents the results of experimental studies that have revealed the molecular mechanisms underlying implantation and placentation controlled by cytokines, chemokines, adhesion molecules, hormones, as well as transcription and growth factors, and have indicated the key regulatory and protective role of melatonin. It has been shown that low production of the hormone and lack of its circadian rhythm underlie the disruption of endogenous antioxidant protection and contribute to oxidative stress leading to the development of preeclampsia. The necessity of using melatonin as a neuroimmunoendocrine marker of pathology is emphasized in this review article, which will allow for developing new approaches to its use for the prevention and treatment of preeclampsia, as well as its adverse consequences, such as obesity, type 2 diabetes mellitus, renal failure, and cardiovascular pathology.
Zitieren
APA
Evsyukova, I. I., & Kvetnoy, I. M. (2022). Melatonin in the pathogenesis of preeclampsia. Journal of obstetrics and women's diseases. https://doi.org/10.17816/jowd103863
Vancouver
Evsyukova II, Kvetnoy IM. Melatonin in the pathogenesis of preeclampsia. Journal of obstetrics and women's diseases. 2022. doi:10.17816/jowd103863
BibTeX
@article{Evsyukova2022,
author = {Evsyukova, Inna I. and Kvetnoy, Igor M.},
title = {Melatonin in the pathogenesis of preeclampsia},
journal = {Journal of obstetrics and women's diseases},
year = {2022},
doi = {10.17816/jowd103863}
}
EUVIMED